Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Exudative Macular Degeneration Clear all
Completed Phase 2Phase 3 Interventional Results available

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

NCT03034772
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
Dorzolamide-timolol, Artificial tears
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
45 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Jun 11, 2026, 4:50 AM EDT
Completed No phase listed Observational

Non-exudative Age-related Macular Degeneration

NCT01712841
View directory record Official record
Conditions
Non-exudative Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)

NCT00725686
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
PF-04523655
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Beverly Hills, California • Pasadena, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Jun 11, 2026, 4:50 AM EDT
Active, not recruiting No phase listed Observational

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

NCT04645212
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
9
States / cities
Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 11, 2026, 4:50 AM EDT
Not listed No phase listed Observational

Non Exudative AMD Imaged With SS-OCT

NCT03688243
View directory record Official record
Conditions
Dry Macular Degeneration
Interventions
SS-OCT imaging
Device
Lead sponsor
Boston Image Reading Center
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

NCT00913744
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Interventions
Ocriplasmin, Sham injection
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Beverly Hills, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Jun 11, 2026, 4:50 AM EDT
Recruiting Phase 3 Interventional

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 11, 2026, 4:50 AM EDT
Terminated No phase listed Observational

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

NCT03699618
View directory record Official record
Conditions
Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
Anti-VEGF, Hemorrhage displacement + Anti-VEGF
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

NCT04640272
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
RBM-007
Drug
Lead sponsor
Ribomic USA Inc
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Southern California Desert Retina Consultants, MC
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)

NCT01213082
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
24GyE proton and Anti-VEGF, 16GyE and anti-VEGF, Sham Irradiation and anti-VEGF
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jun 11, 2026, 4:50 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07496567
View directory record Official record
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Mountain View, California • Lemont, Illinois • Hagerstown, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 11, 2026, 4:50 AM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jun 11, 2026, 4:50 AM EDT
Terminated Phase 3 Interventional

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

NCT00065728
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Central Contact Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2013 · Synced Jun 11, 2026, 4:50 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

NCT00100087
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Ocular Brachytherapy
Device
Lead sponsor
Theragenics Corporation
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 11, 2026, 4:50 AM EDT
Terminated Phase 3 Interventional

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00333216
View directory record Official record
Conditions
AMD
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

NCT02401945
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
DE-120, Aflibercept
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jun 11, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

NCT03452527
View directory record Official record
Conditions
Choroidal Neovascularization, Wet Macular Degeneration
Interventions
ICON-1, aflibercept
Biological
Lead sponsor
Iconic Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jun 11, 2026, 4:50 AM EDT
Not listed Phase 4 Interventional

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

NCT01670162
View directory record Official record
Conditions
Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jun 11, 2026, 4:50 AM EDT
Not listed Phase 2 Interventional

Pneumatic Displacement of Subretinal Hemorrhage With Perfluorocarbon Gases

NCT00161525
View directory record Official record
Conditions
Subretinal Hemorrhage and Exudative Maculopathy
Interventions
Pneumatic displacement
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2011 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

NCT03823300
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 11, 2026, 4:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection

NCT07446582
View directory record Official record
Conditions
Age-Related (Dry) Macular Degeneration
Interventions
Retina imaging device (MSI-120) and AI (DeepMSI AI)
Device
Lead sponsor
AI-Spectral
Industry
Eligibility
40 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Woodbridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 11, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot

NCT00605423
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Fluocinolone Acetonide/Medidur
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Jun 11, 2026, 4:50 AM EDT